Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

BrightEdge Fund

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 17
Average round size
The average size of a deal this fund participated in
Portfolio companies 14
Rounds per year 3.40
Lead investments 0
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 2
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Therapeutics
  • Medical
  • Health Diagnostics

The leading representative office of defined VC is situated in the Atlanta. The venture was found in North America in United States. BrightEdge Fund appeared to be a CVC structure as part of the corporation.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the BrightEdge Fund, startups are often financed by Lilly Asia Ventures, Founders Fund, Data Collective DCVC. The meaningful sponsors for the fund in investment in the same round are Andreessen Horowitz, Westlake Village BioPartners, Verily.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Personal Health, Health Care. The fund has no exact preference in some founders of portfolio startups. If startup sums 2 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Freenome, Navigating Cancer, Castle Biosciences.

Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. Comparing to the other companies, this BrightEdge Fund performs on 4 percentage points more the average number of lead investments.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BrightEdge Fund:
Typical Co-investors
BrightEdge Fund is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BrightEdge Fund:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
China Development Bank International Investment China, Hong Kong, Hong Kong Island
Concord Venture Capital Group Taipei, Taiwan
Deep Track Capital Connecticut, Greenwich, United States
DSM Heerlen, Limburg, The Netherlands
Eqvitec Finland, Helsinki, Southern Finland
First Ally Capital -
Fisher Capital Colorado, Englewood, United States
Ground Squirrel Ventures Boston, Massachusetts, United States
Le Comptoir de l'Innovation France, Ile-de-France, Paris
Mahindra Rise India, Maharashtra, Mumbai
Manfeng Asset China, Shanghai
Mobius Corporate Venture Capital Community of Madrid, Madrid, Spain
NGK SPARK PLUG CO Aichi Prefecture, Japan, Nagoya
Qingdao Fund of Venture Capital Funds -
Shengjin Venture Capital Changning, China, Shanghai
Starting Line Chicago, Illinois, United States
Techweek Chicago, Illinois, United States
Three Gorges Xintai Fund Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Health Care
$400K15 Feb 2023 -


Health Care
Health Diagnostics
Life Science
$203M25 Jan 2023 New York, New York, United States

Alpheus Medical

Health Diagnostics
$14M10 Nov 2022 Oakdale, Pennsylvania, United States

Vincere Health

Health Care
$1M05 Oct 2022 Boston, Massachusetts, United States

Meliora Therapeutics

$11M29 Sep 2022 San Francisco, California, United States


Health Care
$33M19 Sep 2022 Massachusetts, United States

Auron Therapeutics

Health Care
$48M20 Jul 2022 Massachusetts, United States

Persephone Biosciences

Artificial Intelligence
Health Care
$15M19 Jul 2022 San Diego, California, United States


26 Jan 2022 Cambridge, England, United Kingdom
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BrightEdge Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: